Key result
SGLT2 inhibitor use linked to lower 6-month AF recurrence in diabetic patients post-cardioversion.
Why the study?
The study was designed to investigate the effect of SGLT-2 inhibitors on AF recurrence in patients diagnosed with DM who underwent Direct Current Cardioversion.
Do SGLT-2 inhibitors reduce atrial fibrillation recurrence in diabetic patients following direct current cardioversion?
Cohort (n=120)
No
Do SGLT-2 inhibitors reduce atrial fibrillation recurrence in diabetic patients following direct current cardioversion?
SGLT-2 inhibitor use is associated with a significantly lower rate of atrial fibrillation recurrence at 6 months in diabetic patients following successful direct current cardioversion.
Answers are grounded in this paper and cite their sources.
May support adjunctive use in diabetic patients post-cardioversion but should not change practice; leaves open randomized confirmation.
BACKGROUND: The aim of this study was to investigate the effect of SGLT-2 (sodium glucose cotransporter-2) inhibitors on AF (atrial fibrillation) recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic. RESEARCH DESIGN AND METHODS: Consecutive DCCV was performed to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who didn't use SGLT-2 inhibitors). The two groups (SGLT-2 inhibitor user group and control group) were monitored for AF recurrence on the first day, then at one, three, and six months after CV. RESULTS: = 0.03 were found to be independent predictors for AF recurrence. CONCLUSION: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration and SGLT-2 inhibitor non-use were independent predictors, for AF recurrence in DM patients (NCT06951737). CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is: NCT06951737.
No takes yet. Share an insight, caveat, or question.
Yarar et al. (2025) conducted a cohort in Atrial fibrillation and diabetes mellitus (n=120). SGLT-2 inhibitors vs. Non-use of SGLT-2 inhibitors was evaluated on Atrial fibrillation recurrence (p=0.03). SGLT-2 inhibitor use was associated with a lower rate of atrial fibrillation recurrence over 6 months in diabetic patients after cardioversion.
Synapse has enriched 10 related papers. Consider them for comparative context: